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Abstract  
Introduction 
Dalbavancin is an antibiotic within the class of medications known as lipoglycopeptides.  
This medication is given to patients presenting to the hospital with acute skin and skin-
structure infections (ABSSSI).  This is a unique medication because it is given as a one-time 
dose in the outpatient setting and it could prevent patients from requiring admission to 
the hospital. 
Methods 
The emergency department (ED) at Good Samaritan community hospital performed a trial 
period with dalbavancin and data was collected from November 2018 to March 2020.  
Retrospective chart review was performed to obtain patient data and outcomes.  Patients 
would be contacted by a clinical pharmacist within 72 hours of treatment. 
Results 
Ten patients received dalbavancin in the ED during the trial period.  Two patients were 
reached on follow-up and noted improvement in the initial lesion.  Two patients returned 
to the ED within 30 days, and one of these patients was admitted.   
Discussion 
Dalbavancin provides another therapy option to the treatment of ABSSSIs.  The one-time 
dosing is advantageous for outpatient treatment of patients presenting with ABSSSIs.  This 
case series suggests dalbavancin can have positive effects when implemented in 
community hospital settings. 
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Introduction 
Acute bacterial skin and skin-structure infections (ABSSSI) is a common reason 
that patients present to emergency departments (ED) (1).  The causative pathogen in 
patients presenting with ABSSSI is typically gram-positive organisms, particularly 
Staphylococcus aureus (2).  Patients have several options for treatment.  These options 
include inpatient or outpatient treatment in combination with intravenous (IV) or oral 
antibiotics.   
With such a range of treatment options it becomes difficult to determine what 
treatment is best for patients presenting with ABSSSIs.  Inpatient treatment is typically 
reserved for more severe cases of ABSSSIs that may need additional supportive care, and 
outpatient treatment provides a convenient option for patients that present with milder 
cases of ABSSSIs.  Patients treated in the outpatient setting have successful outcomes and 
avoid the inconvenience of being admitted to the hospital (3).  Outpatient treatment 
typically consists of oral antibiotics for ABSSSIs.  Newer antibiotics have been developed 
that allow patients to receive treatment in the outpatient setting in order to avoid 
admission to the hospital for the sole purpose of receiving IV antibiotics. This class of 
antibiotics is known as lipoglycopeptides and includes dalbavancin (4).  Dalbavancin’s 
single IV infusion regimen is Food and Drug Administration (FDA) approved for the 
indication of ABSSSI that are caused by susceptible organisms (5).  Due to the convenience 
of one-time dosing, patients can avoid hospital admission and receive adequate coverage 
for the majority of ABSSSI cases.   
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Dalbavancin has positive public health implications.  Namely, it provides another 
option to the armamentarium of medications used for ABSSSI.  Use of dalbavancin also 
provides convenience for patients and providers through its one-time administration.  
Dalbavancin also allows patients to receive adequate outpatient treatment and thus 
avoid a hospitalization for the treatment of ABSSSI.   
Dalbavancin is currently used at the ED associated with the University of 
Kentucky’s (UK) academic medical center.  UK’s academic medical center has many 
resources such as ED pharmacists and attending physicians, as well as infectious disease 
pharmacists and physicians.  Access to these resources and personnel allow for proper 
administration, documentation and follow-up for dalbavancin through a collaborative 
institutional protocol.  The community hospital associated with UK, known as Good 
Samaritan, does not have a dedicated ED pharmacist at this time.  A trial period of 
dalbavancin utilization was initiated at Good Samaritan’s ED.  The trial period was initiated 
in November of 2018 and included 10 patients.    
This retrospective case series was performed for patients that received 
dalbavancin within the ED at Good Samaritan Hospital.  This case series aims to describe 
the results of patients receiving dalbavancin at Good Samaritan, as well as identify areas 
of process improvement for the administration of dalbavancin within a smaller 
community ED setting.   
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Literature Review 
Presentation of ABSSSI 
ABSSSI is a common condition that is seen by practitioners within emergency 
departments.  The FDA defines ABSSSI as cellulitis/erysipelas, wound infection, and major 
cutaneous abscess, with a surface area of the lesion greater than or equal to 75m2.  In 
addition, there are two categories of ABSSSI: purulent, which includes cellulitis and 
erysipelas, and nonpurulent, which includes abscesses (6).  The variation could range from 
those presenting with minor cases of uncomplicated cellulitis to those presenting with a 
major cutaneous abscess, along with systemic symptoms (7).  While these patients can 
have a multitude of presentations, initial treatment will typically be directed towards 
gram-positive cocci (4).  Others present with gram-negative pathogens, anaerobes or a 
mixture.  These patients can typically be identified through specific risk factors and 
comorbidities that are listed in table 1 (8).   
Table 1. Gram Negative Organism Risk Factors 
Risk Factors for Gram-Negative or 
anaerobic infections 
Co-morbidities associated with gram-
negative or anaerobic infections 
Surgical site infections 
Axillary cavity 
Gastrointestinal tract 
Perineum 
Female genital tract 
Diabetes mellitus 
Cirrhosis 
Intravenous drug abuse 
Subcutaneous drug abuse 
 
Patients that present to the ED with ABSSSI can be treated in the outpatient 
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setting and the Infectious Diseases Society of America (IDSA) recommends this route of 
treatment, when possible (9).  However, there are patients that present to the ED that 
will ultimately need to be hospitalized.  Determination of proper route of treatment is 
subjective and can vary between providers.  One study found that patients were most 
likely to be hospitalized when they needed IV antibiotics, had a history of fever, presented 
with a larger lesion, had any co-morbidity and were age >65 years.  However, the study 
also found that nearly all the patients were admitted to non-critical areas and few had 
serious complications.  This finding raises the possibility that patients could have 
experienced successful outcomes with outpatient treatment (10).  It must also be 
considered that patients treated within the inpatient setting are exposed to risks such as 
adverse drug reactions and infection (11).   
Treatment of ABSSSI 
Patients that present to the ED with ABSSSI have a multitude of treatment options.  
These treatments are typically aimed at gram-positive organisms such as Staphylococcus 
aureus and Streptococcus spp. (12).  The 2019 review to the IDSA ABSSSI guidelines notes 
that methicillin-resistant Staphylococcus aureus (MRSA) needs to be considered when 
treating patients who present with ABSSSI (4).  This consideration is paramount within 
areas that have higher rates of MRSA demonstrated by antibiogram patterns.  There are 
many drugs that have good activity against MRSA, but it becomes difficult to determine 
which choice is the best for patients presenting to the ED with ABSSSI.  
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Table 2. Antibiotics Available for ABSSSI Treatment 
 
Drug Considerations in therapy 
Vancomycin Drug of choice for MRSA; requires drug 
monitoring; nephrotoxic effects; IV only 
Linezolid Bacteriostatic; hematologic effects; oral 
or IV 
Tedizolid Bacteriostatic; hematologic effects; oral 
or IV 
Clindamycin Bacteriostatic; inducible resistance with 
MRSA; risk of Clostridioides difficile; 
oral or IV 
Daptomycin Bactericidal; potential for myopathies; IV 
only 
Ceftaroline Bactericidal; IV only 
Doxycycline Bacteriostatic; oral or IV 
Trimethoprim-sulfamethoxazole  Bactericidal; oral or IV 
Delafloxacin Tendon rupture; CNS effects; oral or IV 
Omadacycline  Oral or IV 
Dalbavancin Bactericidal; IV only; single infusion 
Oritavancin Bactericidal; IV only; single infusion 
 
As noted in table 2, there are many options for treatment of patients presenting 
with ABSSSI.  Vancomycin is the drug that is commonly started as the initial treatment for 
patients presenting with more severe ABSSSIs.  Vancomycin is chosen due to its superb 
coverage of gram-positive organisms, as well as its effectiveness against MRSA (13).  
However, vancomycin is an IV drug that is typically given twice daily, and patients will 
often be admitted to the hospital in order to receive the proper dosing.   
Drawbacks to the use of vancomycin include risk of kidney injury with high trough 
concentrations (>20mg/L), higher daily doses (>4g per day), longer duration of therapy 
(>7 days) and concomitant dosing with other antimicrobials such as piperacillin-
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tazobactam (14, 15).  Due to the risk of nephrotoxicity, vancomycin requires therapeutic 
drug monitoring and dosage adjustments that can be time and labor intensive (16).  
Conversely, patients that present to the ED with ABSSSI and mild to no systemic 
symptoms can be candidates for outpatient treatment.  Outpatient is preferred, when 
possible, due to cost savings and the avoidance of unintended consequences associated 
with hospital admissions (3, 11).  Traditionally, patients that receive outpatient treatment 
will receive oral medications due to the convenience from a patient’s perspective.  As 
noted in table 2, there are several medications that have oral options, which include 
linezolid, doxycycline and trimethoprim-sulfamethoxazole.  These all have coverage 
against MRSA and can be effective options when a patient is deemed to be a candidate 
for outpatient therapy.  In addition, patients that are admitted to the hospital to receive 
IV antibiotics may be discharged within a few days after showing signs of improvement 
and then can be switched to oral antibiotics to finish a 7 to 10-day treatment course (4).   
Patients can receive IV antibiotics within the outpatient setting and this is known 
as outpatient parenteral antibiotic therapy (OPAT).  The IV medications will be 
administered through a temporary IV line that is placed.  This method allows patients to 
receive proper antibiotic therapy within their own home, an infusion center or a long-
term medical facility.  This method is a convenient option for patients that have help from 
caregivers or in-home medical staff (home health nurses, etc.).  However, not every 
patient is a candidate to receive OPAT.  There needs to a competent and adherent patient 
or caregiver within the home of a patient receiving OPAT.  This adult also must be able to 
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learn and perform sterile infusion, as well as communicate with a medical team (17).  Any 
of the IV drugs listed in table 2 can be utilized for patients within the outpatient setting.   
There are several downsides to utilizing OPAT.  As mentioned, this option requires 
patients to have an IV access line placed and this can lead to adverse events.  This IV 
access line can become infected without proper sanitizing techniques, or a clot can 
develop, which prevents drug from being properly administered through the line.  In 
addition to this, several antibiotics need therapeutic drug monitoring due to risk of 
incorrect drug concentration levels and this requires weekly check-ups with a healthcare 
provider (17).   
Dalbavancin is a new IV medication that can be used within the outpatient setting.  
It is unique in the fact that it is a single IV dose which is FDA-approved for the treatment 
of ABSSSIs.  The convenience of a one-time dose is very appealing to patients, and it 
avoids therapeutic drug monitoring or the need for an IV access line to be placed.  Also, 
proper dalbavancin utilization could lead to cost savings through avoidance of inpatient 
hospital days (18).  Dalbavancin has a favorable side effect profile with mild adverse 
reactions being identified.  The major adverse events include nausea, headache and 
diarrhea.  Also, dalbavancin has little effect on cytochrome P450 substrates and therefore 
there are few clinically relevant drug interactions (5).   
Outpatient dalbavancin versus inpatient treatment 
The FDA’s approval of dalbavancin for the treatment of ABSSSI raises the question 
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of dalbavancin’s place in therapy.  Studies note that one role in therapy could be for 
patients that are being admitted to the hospital for the sole purpose of receiving IV 
antibiotics.  Talan et al found that 41.5% of patients presenting with ABSSSI were 
admitted to the hospital for the sole purpose of receiving IV antibiotics and none of these 
patients required intensive critical unit (ICU) transfer (10).  This finding demonstrates that 
many patients could utilize outpatient therapy due to the lack of high-level care needed.  
To add to this, data from 2008 to 2010 showed that patients presenting with ABSSSIs that 
were subsequently hospitalized, had a mortality of 0.5%.  This statistic demonstrates that 
many ABSSSI patients have no need to be hospitalized (19).  Assuming these patients have 
no contraindications to dalbavancin, this could be the area where dalbavancin could be 
utilized for cost-savings and patient convenience.   
Another study compared the use of vancomycin followed by oral linezolid to the 
use of dalbavancin weekly for the treatment of patients with ABSSSIs.  Specifically, these 
were patients with one or more systemic signs of infection who were thought to need at 
least three days of IV therapy (20).  Previously dalbavancin had been approved for a 
regimen of 1 gram on day 1 followed by 500mg on day 8, but it was later proved that a 
single 1500mg infusion was noninferior (21). The study found that dalbavancin was not 
inferior to the conventional regimen of IV plus oral antibiotics.  In addition to this, patients 
receiving dalbavancin had fewer side effects as compared to those that received 
vancomycin-linezolid combination (20).   
There is good evidence for using dalbavancin for patients that would typically be 
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admitted to the hospital for the sole purpose of receiving IV antibiotics.  However, it 
becomes important to understand when patients are not candidates for dalbavancin and 
should be admitted to the hospital.  Currently there is not a definitive algorithm for when 
patients should be hospitalized due to an ABSSSI.  IDSA guidelines note that patients that 
should likely be admitted to the hospital include those with signs of sepsis, suspicion of 
deep tissue infections (i.e. necrotizing fasciitis), or exacerbation of comorbidities (4).  
These patients are best managed within the inpatient setting due to medical concerns 
that go beyond a skin infection.  Also, if a patient presents with symptoms or 
comorbidities listed in table 1, they will need additional coverage that typically warrants 
admission to the hospital.   
Use of dalbavancin at the University of Kentucky Medical Center 
Currently, dalbavancin is utilized within the University of Kentucky emergency 
department and has shown favorable outcomes.  In 2016, a case series was performed in 
order to assess the feasibility of using dalbavancin (22).  The antimicrobial stewardship 
team at UK developed guidelines to allow for proper selection of patients who could 
receive dalbavancin.  As the literature shows, the guideline first determined whether the 
patient would be admitted to the hospital for IV antibiotics to treat ABSSSI.  If the patient 
is 18 years of age or older and has a lesion 75 cm2 or greater, then they become a 
candidate for dalbavancin.  However, there are several contraindications to the use of 
dalbavancin, which are listed in table 3 (23).   
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Table 3. Contraindications to Dalbavancin 
 
Contraindications to dalbavancin 
- Diabetic foot infection/compromised vascularity  
- Necrotizing fasciitis/gangrene  
- Altered mental status  
- Prior antibiotic failure and requires inpatient support  
- Bacteremia, endocarditis, osteomyelitis, catheter infection  
- Unstable comorbidities (ex: diabetic ketoacidosis, acute exacerbation)  
- Immunocompromised (ex: CD4 < 200 cells/mm3 , neutrophils < 500 cells/mm3 
, uncontrolled diabetes)  
- Burn  
- Severe sepsis/shock  
- Severe vancomycin allergy  
- Severe hepatic disease  
- Surgical site infection  
- Pregnancy 
 
 
Following up with patients that receive dalbavancin is an important part of the 
treatment algorithm.  The protocol developed at UK has the emergency department 
pharmacist follow-up with patients within the next 72 hours to monitor improvement.  
This is the time period when most patients experience clinical improvement and is an 
endpoint that has been used for outcomes in previous studies (24).  After the follow-up 
interaction, patient’s clinical outcomes are recorded within REDCap™ (22).   
The University of Kentucky has a community hospital that is affiliated with their 
healthcare system, Good Samaritan Hospital.  This community hospital is a smaller 
institution that is equipped with an ED.  However, Good Samaritan’s ED does not have an 
emergency department pharmacist on site, who is typically responsible for screening, 
documentation and follow-up, as it relates to dalbavancin.  Thus, dalbavancin is utilized 
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less frequently at Good Samaritan’s ED and it remains to be seen if dalbavancin will be 
effective within this community hospital.   
Purpose 
This case series was performed to describe the results of utilizing dalbavancin 
within the community hospital setting at Good Samaritan’s ED.  The primary goal of this 
case series was to assess patient outcomes for those that received dalbavancin within 
Good Samaritan’s ED from November 2018 to March 2020.  The secondary goal was to 
determine process improvement areas, including follow-up and documentation 
opportunities.   
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Methods 
All data were extracted from electronic medical records (EMR) of patients that 
presented to the ED at Good Samaritan Hospital.  Approval was obtained from the 
University of Kentucky Institutional Review Board (IRB) to extract and analyze 
retrospective health record data for patients that received dalbavancin within the ED at 
Good Samaritan Hospital.  The approved time period for data collection begins in 
November, 2018, and ends October 26, 2020.  The inclusion criteria for the case series 
were patients ≥18 years of age with an ABSSSI ≥ 75 cm2 that had received dalbavancin at 
Good Samaritan’s ED from November 2018 to March 2020.  The business partner director 
for pharmacy services at UK was able to obtain the correct patient records based on billing 
for dalbavancin.  Patients were also identified by performing a keyword search in the 
admission History and Physical (H&P).   
Through retrospective chart review, the patient characteristics were determined. 
Patients’ age and gender were pulled directly from the patient profile.  The ED admission 
note was reviewed for the determination of each patient’s diagnosis, comorbid conditions 
and any past medical history related to ABSSSIs, as well as any hospital visits after the 
administration of dalbavancin. 
Because dalbavancin administration was a new process, physicians needed to 
ensure patients were appropriate candidates for dalbavancin therapy.  Table 4 (23) 
identifies those who would need to be contacted for approval of dalbavancin 
administration.  There was documentation within each patient’s profile to describe the 
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appropriateness of dalbavancin.  All other information related to the screening process, 
additional therapy, administration of dalbavancin and the patient follow-up were located 
in this documentation.  The dalbavancin screening determination process is presented in 
figure 1 (23).  
Table 4. Provider Approval for Dalbavancin Administration  
 
Day  Time  Provider Approval Needed  
Weekdays  0600 - 1800  ED Attending Physician  
GS Clinical Pharmacist On Call  
ID Pharmacist or Physician  
 1800 - 0600 ED Attending Physician  
GS Operations Pharmacist  
Weekends  0600 - 1800  ED Attending Physician  
GS Clinical Pharmacist On Call  
 1800 - 0600 ED Attending Physician  
GS Operations Pharmacist  
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Figure 1. Dalbavancin Approval Algorithm 
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Results 
From November 2018 to March 2020, patients that received dalbavancin were 
identified.  At the end of the trial period, ten patients had received dalbavancin.  The 
average age of patients receiving dalbavancin was 42.7 years, with a range of 23 to 68.  
Seven of the patients were female and three male.   
During the trial period, the patients’ lesions were identified and described.  Five 
(50%) of the patients presenting to the ED had an ABSSSI occurring on their lower 
extremities.  Four (40%) patients presented with ABSSSI occurring on their upper 
extremities and 1 (10%) presented with ABSSSI on their abdomen.   
Most patients during this trial period had documented comorbidities.  The most 
common comorbidity observed in this case series was IV drug use (40%).  Other 
documented comorbidities included hypertension (HTN) (20%), hyperlipidemia (HLD) 
(20%) and morbid obesity (20%).  Wound culture data was obtained for 2 (20%) patients.  
Dalbavancin properly covered the MRSA found in one patient and the MSSA in the other.  
The patient with MSSA also had growth of Escherichia coli and Enterobacter cloacae, this 
patient received an additional antibiotic due to the gram-negative organisms. 
Two patients were contacted for follow-up within 72 hours, one of which received 
an incision and drainage of abscess the next day.  A third patient returned to the ED within 
72 hours, and a fourth patient returned 16 days later to be admitted due to a gram-
negative organism, Pseudomonas fluorescens, in the bloodstream.  The two patients 
21 
 
contacted noted improvement in their initial lesion.  The third patient that returned to 
the ED within 72 hours presented with new skin lesions.  This patient noted improvement 
in their initial lesion, but due to an underlying condition this patient presented with new 
skin lesions.  The patient that was admitted 16 days later for Pseudomonas fluorescens in 
their bloodstream also had a positive wound culture showing MRSA.  This patient received 
oral levofloxacin for their bacteremia. 
Adverse effects were minimal, as they were only noted in two (20%) patients.  One 
patient experienced nausea during their infusion of dalbavancin.  The other patient 
experienced dizziness during their infusion of dalbavancin.   
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Table 5. Results of Dalbavancin administration 
  
Gender Age ED Diagnosis Comments/Notes Comorbid 
Conditions 
I&D Outcome 
F 59 Cellulitis of right 
lower extremity 
Previous use of 
antibiotics for cellulitis 
with Bactrim and 
Keflex, no cultures 
taken, WBC of 6.94, 
dizziness experienced 
during infusion 
HTN, morbid 
obesity, 
T2DM, HLD 
N/A Follow-up phone call 
from ED pharmacist - 
patient reported 
improvement 
F 68 Cellulitis of right 
upper extremity  
Had previous episodes 
of cellulitis and had 
taken clindamycin, 
negative BC, WBC of 
14 
Breast cancer N/A No follow-up 
information 
M 38 Cellulitis of right 
upper extremity 
Frequent hospital visits 
due to IV drug abuse, 
negative BC, WBC of 
6.8 
IVDU N/A No follow-up 
information, subsequent 
hospitalizations due to 
IVDU 
F 37 Cellulitis of 
bilateral lower 
extremities 
Negative BC, WBC of 
13.8 
IVDU N/A No follow-up 
information 
F 28 Stomach abscess Patient was on chronic 
doxycycline and had 
recently been taking 
clindamycin as well for 
abscesses, negative BC, 
WBC of 14, nausea 
experienced during 
infusion 
Hidradenitis 
suppurativa, 
morbid 
obesity, 
asthma 
N/A Patient returned to ED 
with new abscess but 
noted improvement on 
the initial abscess 
F 28 Abscess of right 
arm 
History of failed oral 
antibiotics, signs of 
UTI, positive BC for 
Pseudomonas 
fluorescens, WBC of 
7.3 
IVDU, 
endometriosis, 
HPV 
Yes - MRSA No follow-up, patient 
presented 16 days later 
with fever – prescribed 
levofloxacin due to 
initial positive BC 
F 44 Cellulitis of 
bilateral upper 
extremities 
Chief complaint was 
stomach pain, cellulitis 
was related to injection 
sites, no BC, WBC of 
14.6 
IVDU, 
hepatitis C 
N/A No follow-up 
information 
F 45 Cellulitis of 
bilateral thighs 
and buttocks 
Received concomitant 
antibiotics for STD 
prophylaxis and UTI, 
negative BC, WBC of 
7.2 
Chronic back 
pain 
N/A No follow-up 
information 
M 57 Cellulitis/abscess 
of right lower 
extremity 
Presented to ED next 
day due to positive BC 
for Staphylococcus 
aureus, received 
abscess I&D, WBC of 
16.2 
HTN, HLD Yes- MSSA, 
E. coli, 
Enterobacter 
cloacae 
Follow-up phone call 
from ED pharmacist – 
patient reported 
improvement – patient 
followed up with PCP 
for other bacteria and 
received ciprofloxacin 
M 23 Bilateral lower 
extremity 
cellulitis 
Previously hospitalized 
for cellulitis and 
received vancomycin 
with oral transition to 
Bactrim, negative BC, 
WBC of 13.4 
None  N/A No follow-up 
information 
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Limitations 
There are several limitations to this study.  This was a retrospective case series 
with a small sample of 10 patients.  All data was extracted from an EMR.  In addition, this 
case series was performed at a single hospital’s ED, limiting our ability to draw 
conclusions.  Follow-up information was missing for the majority of patients in this case 
series.  Long-term effects of dalbavancin cannot be properly tracked if follow-up 
information is not obtained from patients.     
 
Discussion  
The case series performed at Good Samaritan’s ED showed improvement of 
symptoms and minimal side effects for those that received dalbavancin for patients who 
were able to be contacted.  This finding suggests that dalbavancin, when implemented 
properly, may be a viable option for patients presenting to a community ED with an 
ABSSSI.  For the two patients that were contacted within 72 hours, both patients noted 
improvement of the initial lesion.  A third patient returned to the ED for new skin lesions 
but noted the initial lesion had improved.  This patient-reported improvement suggests 
positive outcomes for those that received dalbavancin and were available for follow-up.  
This finding aligns with previous studies that show positive outcomes for those receiving 
dalbavancin for ABSSSIs (20, 25).   
Patients with documented follow-up showed improvement but this case series 
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demonstrates the problem of loss to follow-up.  The majority (60%) of patients had no 
documented follow-up from either the pharmacist or subsequent hospital visits.  This is 
problematic for several reasons.  Drug effects cannot be monitored when outcomes are 
unavailable.  It becomes difficult to properly monitor effects of a drug when outcomes 
cannot be tracked.  However, this case study is not alone in experiencing difficulties with 
patient follow-up.  A previous study analyzing the implementation of dalbavancin 
demonstrated difficulties in following up with patients after they have left the hospital 
(26).   
IV drug abuse was a common comorbidity among patients within this case series.  
Previous studies have shown that those who inject IV drugs have a greater risk for 
infectious diseases, including bacterial skin infections (27, 28).  The single IVDU in the case 
series who had culture results showed MRSA as the offending agent.  Not only is 
dalbavancin effective for more difficult pathogens such as MRSA, but it also provides a 
convenient treatment regimen that can improve compliance.  Other outpatient 
treatments require oral or IV administration over several days, which introduces the risk 
of patient non-compliance.  Dalbavancin is monitored for the one-time dose and 
eliminates any risk of non-compliance, which is a concern within the IVDU population 
(29).  When a full dose of antibiotics is taken appropriately there is a better chance of 
successful treatment and a lower chance of antibiotic resistance.   
Non-compliance is not a problem that is specific to IVDU.  Previous studies have 
shown that the population in general has poor adherence rates, with nearly 15% stopping 
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their antibiotics early (30).  Noncompliance puts patients at risk of treatment failure in 
the short term.  In the long term, non-compliance contributes to the public health issue 
of antibiotic resistance.  This problem may not present as quickly as treatment failure, but 
antibiotic resistance still has far-reaching effects.  Infections with antibiotic resistant 
organisms are harder to treat and can have worse outcomes.  The CDC estimates that 
nearly 3 million people annually in the U.S. are infected with an antibiotic resistant 
bacteria or fungi.  In addition, the CDC estimates that nearly 35,000 people will die of 
these difficult-to-treat infections (31).  Completing antibiotic courses is a simple yet 
effective method to combat antibiotic resistance.  The one-time dosing of dalbavancin 
offers an effective solution when providers are concerned about a patient’s adherence. 
Adverse effects appear to have been minimal in this case series with only two 
patients experiencing problems associated with dalbavancin administration, although the 
majority of patients were lost to follow-up.  One patient experienced nausea as the 
infusion was being given.  The other patient experienced dizziness that was associated 
with the infusion.  Both reactions align with adverse effects reported in previous 
dalbavancin studies.   The phase III trials that proved the non-inferiority of dalbavancin to 
comparators showed a favorable side effect profile.  These studies noted common side 
effects to be nausea, diarrhea, and pruritus (20).  These are mild side effects when 
compared to the side effects of similar drugs such as vancomycin and linezolid.  
Vancomycin can be associated with more severe side effects such as acute kidney injury 
(14).  In addition, a serious side effect associated with linezolid is hematologic changes 
such as thrombocytopenia and anemia (32).  If patients were to have a kidney deficiencies 
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or previous hematologic abnormalities, dalbavancin could be a reasonable alternative as 
opposed to vancomycin or linezolid.   
A potential benefit of dalbavancin is the cost effectiveness.  A cost analysis was 
not performed in this case series, but previous literature shows potential cost-savings 
from the use of dalbavancin.  This is because dalbavancin is traditionally used for patients 
that would be admitted to the hospital.  Instead of incurring the high cost of a hospital 
stay, patients receive their dalbavancin infusion in the ED and then are discharged.  A 
retrospective study at UK’s academic medical center compared the cost of dalbavancin to 
a group of patients that were admitted to the hospital for ABSSSIs.  The patients that 
received dalbavancin had a direct cost avoidance of $4,560 (33), demonstrating 
substantial cost-savings when dalbavancin is properly utilized.   
Implications 
Dalbavancin is a drug that has several benefits when treating ABSSSI.  Dalbavancin 
plays a unique role because it is an outpatient treatment that can be used for patients 
who would have previously been admitted to the hospital for IV antibiotics.  On a larger 
scale, this case series adds to the growing body of literature that illustrates the potential 
effectiveness of dalbavancin.   
This case series has public health implications regarding antibiotic resistance.  
More frequent use of dalbavancin has the potential reduce patients’ prescription 
antibiotic nonadherence in patients and thus reduce antibiotic resistance.  Healthcare 
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providers can confirm that patients receive a full antibiotic regimen with the 
administration of dalbavancin thus ensuring that patients are adequately treated, while 
mitigating the chance of antibiotic resistance.  
At the institutional level, this case series adds to the literature by addressing the 
outcomes of implementing dalbavancin within a community ED. Community EDs do not 
have the resources of larger academic medical centers, and this could make it more 
difficult to justify implementing a new antibacterial such as dalbavancin.  This case series 
provides one example of the processes that could be implemented to begin using 
dalbavancin.  Also, this case series provides insight into the problems that can be 
encountered when implementing dalbavancin within a community ED.   
This case series also demonstrates the infrequent use of dalbavancin.  This case 
series extended over sixteen months but there were only ten patients that received 
dalbavancin.  Providers’ comfort with prescribing dalbavancin appears to be an obstacle.  
Providers know what to expect when prescribing a drug such as vancomycin for ABSSSIs.  
Dalbavancin, however, is a new drug that has an unconventional dosing regimen.  This 
situation presents an opportunity for pharmacists to educate providers on dalbavancin’s 
place in therapy.  In addition, pharmacy staff can work with providers to ensure proper 
protocols for dalbavancin administration.  With these measures in place, cost savings and 
convenient dosing of dalbavancin can be fully realized (34).  
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